Target Name: OLR1
NCBI ID: G4973
Review Report on OLR1 Target / Biomarker Content of Review Report on OLR1 Target / Biomarker
OLR1
Other Name(s): Ox LDL receptor 1 | Oxidized low density lipoprotein receptor 1, transcript variant 1 | Scavenger receptor class E, member 1 | CLEC8A | hLOX-1 | Oxidized low-density lipoprotein receptor 1, soluble form | oxidized low-density lipoprotein receptor 1, soluble form | SCARE1 | oxidized low density lipoprotein (lectin-like) receptor 1 | OTTHUMP00000238954 | OLR1 variant 3 | OLR1_HUMAN | OLR1 variant 1 | Lectin-like oxLDL receptor 1 | scavenger receptor class E, member 1 | LOX1 | C-type lectin domain family 8 member A | Oxidized low density lipoprotein receptor 1, transcript variant 3 | Lectin-like oxidized LDL receptor 1 | Oxidized low-density lipoprotein receptor 1 (isoform 1) | LOXIN | OTTHUMP00000238950 | Oxidized low-density lipoprotein receptor 1 | OTTHUMP00000238955 | SLOX1 | ox LDL receptor 1 | OTTHUMP00000238958 | LOX-1 | Lectin-type oxidized LDL receptor 1 | lectin-type oxidized LDL receptor 1 | Oxidised low density lipoprotein receptor 1 (LOX-1) | Ox-LDL receptor 1 | Oxidized low-density lipoprotein receptor 1 (isoform 3) | oxidized low density lipoprotein receptor 1

OLR1: A Potential Drug Target for Heart Disease and Cancer

OLR1 (Ox LDL receptor 1) is a protein that is expressed in the liver and is involved in the uptake and processing of low-density lipoprotein (LDL) cholesterol, which is a major risk factor for the development of heart disease. OLR1 is a potential drug target or biomarker for the treatment of various diseases, including heart disease, diabetes, and cancer.

The OLR1 protein is composed of 158 amino acid residues and has a calculated molecular weight of 19.9 kDa. It is located on the surface of the liver and is involved in the processing of LDL cholesterol. LDL cholesterol is a major risk factor for the development of heart disease, as it can cause the buildup of plaque in the arteries, which can lead to the formation of blood clots that can cause heart attacks and strokes.

OLR1 is a critical protein for the proper functioning of the liver, as it helps to remove LDL cholesterol from the body. The liver is responsible for producing and storing fat in the body, and LDL cholesterol is one of the primary types of fat that the liver produces. When the liver produces LDL cholesterol, it needs to be processed and removed from the body to prevent the buildup of excessive cholesterol in the blood. OLR1 is involved in this process by helping to transport LDL cholesterol from the liver to the body's fat cells for processing and removal.

OLR1 is also involved in the regulation of cellular signaling pathways that are important for the development and progression of various diseases, including cancer. For example, OLR1 has been shown to be involved in the regulation of the PI3K/AKT signaling pathway, which is important for the development and survival of cancer cells.

In addition to its role in the regulation of cellular signaling pathways, OLR1 is also a potential drug target or biomarker for the treatment of various diseases. For example, OLR1 has been shown to be involved in the development of cancer, and studies have suggested that inhibiting OLR1 may be a promising strategy for the treatment of cancer.

One of the potential benefits of targeting OLR1 as a drug target is its potential to reduce the production of LDL cholesterol in the body. By inhibiting the activity of OLR1, it is possible to reduce the amount of LDL cholesterol that is produced by the liver and subsequently removed from the body. This could lead to a reduction in the risk of the development of heart disease and other conditions associated with high levels of LDL cholesterol.

Another potential benefit of targeting OLR1 as a drug target is its potential to improve the levels of good cholesterol (HDL) in the body. HDL cholesterol is a beneficial type of cholesterol that helps to lower the risk of heart disease, and OLR1 is involved in the regulation of its production. By inhibiting the activity of OLR1, it is possible to increase the levels of HDL cholesterol in the body, which could lead to a reduction in the risk of heart disease.

In addition to its potential to reduce the production of LDL cholesterol and improve HDL cholesterol levels, OLR1 is also a potential biomarker for the diagnosis and monitoring of various diseases. For example, OLR1 has been shown to be involved in the development of cancer, and its levels have been associated with the severity of certain types of cancer. Additionally, OLR1 levels have been shown to be involved in the regulation of cellular signaling pathways that are important for the development and progression of various diseases, including cancer.

In conclusion, OLR1 is a protein that is expressed in the liver and is involved in the uptake and processing of LDL cholesterol. It is a potential drug target or biomarker for the treatment of various diseases, including heart disease, diabetes, and cancer. By inhibiting the activity of OLR1, it is possible to reduce the production of LDL cholesterol and improve HDL cholesterol levels, as well as

Protein Name: Oxidized Low Density Lipoprotein Receptor 1

Functions: Receptor that mediates the recognition, internalization and degradation of oxidatively modified low density lipoprotein (oxLDL) by vascular endothelial cells. OxLDL is a marker of atherosclerosis that induces vascular endothelial cell activation and dysfunction, resulting in pro-inflammatory responses, pro-oxidative conditions and apoptosis. Its association with oxLDL induces the activation of NF-kappa-B through an increased production of intracellular reactive oxygen and a variety of pro-atherogenic cellular responses including a reduction of nitric oxide (NO) release, monocyte adhesion and apoptosis. In addition to binding oxLDL, it acts as a receptor for the HSP70 protein involved in antigen cross-presentation to naive T-cells in dendritic cells, thereby participating in cell-mediated antigen cross-presentation. Also involved in inflammatory process, by acting as a leukocyte-adhesion molecule at the vascular interface in endotoxin-induced inflammation. Also acts as a receptor for advanced glycation end (AGE) products, activated platelets, monocytes, apoptotic cells and both Gram-negative and Gram-positive bacteria

The "OLR1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OLR1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

OMA1 | OMD | OMG | OMP | Oncostatin-M Receptor | ONECUT1 | ONECUT2 | ONECUT3 | OOEP | OOSP1 | OOSP2 | OPA1 | OPA1-AS1 | OPA3 | OPALIN | OPCML | OPHN1 | Opioid receptor | OPLAH | OPN1LW | OPN1MW | OPN1MW3 | OPN1SW | OPN3 | OPN4 | OPN5 | OPRD1 | OPRK1 | OPRL1 | OPRM1 | OPRPN | OPTC | OPTN | OR10A2 | OR10A3 | OR10A4 | OR10A5 | OR10A6 | OR10A7 | OR10AA1P | OR10AB1P | OR10AC1 | OR10AD1 | OR10AF1P | OR10AG1 | OR10AK1P | OR10C1 | OR10D1P | OR10D3 | OR10D4P | OR10G2 | OR10G3 | OR10G4 | OR10G7 | OR10G8 | OR10G9 | OR10H1 | OR10H2 | OR10H3 | OR10H4 | OR10H5 | OR10J1 | OR10J2P | OR10J3 | OR10J5 | OR10K1 | OR10K2 | OR10P1 | OR10Q1 | OR10R2 | OR10S1 | OR10T2 | OR10V1 | OR10W1 | OR10X1 | OR10Z1 | OR11A1 | OR11G2 | OR11H1 | OR11H12 | OR11H13P | OR11H2 | OR11H5P | OR11H6 | OR11H7 | OR11J2P | OR11J5P | OR11K2P | OR11L1 | OR11M1P | OR12D2 | OR12D3 | OR13A1 | OR13C2 | OR13C3 | OR13C4 | OR13C5 | OR13C8 | OR13C9 | OR13D1